Rezdiffra (Resmetirom) Pediatric Safety: What Parents and Clinicians Need to Know About Use in Children Under 12

What Is Resmetirom and Why Does the Pediatric Question Matter?

Resmetirom is a selective thyroid hormone receptor-beta agonist taken as a once-daily oral tablet. The FDA approved it on March 14, 2024, under the brand name Rezdiffra, making it the first drug ever approved specifically for metabolic dysfunction-associated steatohepatitis (MASH) in adults. The approval was based on histological endpoints, not surrogate biomarkers alone.

The pediatric question is not abstract. Nonalcoholic fatty liver disease (now termed MASLD) affects an estimated 10% of American children overall, rising to roughly 38% in children who have obesity. With no approved pharmacotherapy for pediatric MASH, clinicians and families are increasingly asking whether an adult-approved drug could be used in younger patients.

The short answer: no pediatric safety, pharmacokinetic, or efficacy data exist for resmetirom in children under 12, and current labeling explicitly states that safety and efficacy in patients under 18 have not been established.

The Scale of Pediatric MASLD

A 2023 analysis published in Hepatology estimated that MASLD now affects approximately 8-10 million U.S. Children, with the highest burden in Hispanic and Asian adolescent males. Liver biopsy-confirmed NASH in children is less common than in adults but carries the same long-term fibrosis risk. Children with MASH and stage F2-F3 fibrosis face a decades-long disease course that could theoretically benefit from early intervention, but that theoretical benefit does not override the absence of safety data.

Why "Adults Only" Is a Hard Boundary Here

The FDA's pediatric labeling section of the Rezdiffra prescribing information states explicitly: "Safety and effectiveness in pediatric patients have not been established." This language appears under Section 8.4 of the full prescribing information, and it means no pediatric clinical trials were submitted to or reviewed by the FDA at the time of approval. Off-label prescribing in children under 12 would proceed without any regulatory-reviewed safety signal, dose-finding, or pharmacokinetic dataset.

FDA Approval and Labeling: What the Prescribing Information Actually Says

The Rezdiffra full prescribing information, available through the FDA, outlines the approved indication as: "treatment of adults with noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis)." [1]

Section 8.4: Pediatric Use

Section 8.4 of the label contains no efficacy or safety tables for pediatric patients. There is no weight-based dosing table for children, no age-adjusted pharmacokinetic data, and no reference to an ongoing pediatric study. The Pediatric Research Equity Act (PREA) ordinarily requires sponsors to conduct pediatric studies, but PREA waivers or deferrals may apply when a disease does not occur in the pediatric population in a clinically meaningful way, or when studies are impractical. Madrigal Pharmaceuticals received a deferral, meaning pediatric studies may be required later but were not mandated before initial approval.

Dosing in Adults (for context)

Adult dosing is weight-stratified: 80 mg once daily for patients weighing <100 kg, and 100 mg once daily for those weighing ≥100 kg. These thresholds were derived from adult pharmacokinetic modeling. No equivalent modeling has been done in pediatric populations, where body composition, hepatic enzyme activity, and plasma protein binding differ substantially from adults.

MAESTRO-NASH Trial: The Evidence Base Behind the Approval

The key trial supporting FDA approval was MAESTRO-NASH, a phase 3, randomized, double-blind, placebo-controlled trial published in the New England Journal of Medicine in 2024. [2]

Trial Design and Population

MAESTRO-NASH enrolled 966 adults with biopsy-confirmed MASH and fibrosis stage F1b-F3. The mean age of participants was 56 years. Patients with decompensated cirrhosis were excluded. No participants under 18 were enrolled. The youngest patient in the trial was an adult, and the study was not designed to generate pediatric data.

Key Efficacy Outcomes

At 52 weeks, 25.9% of patients receiving resmetirom 100 mg achieved NASH resolution with no worsening of fibrosis, compared with 14.2% on placebo (P<0.001). [2] In the 80-mg arm, 24.2% achieved NASH resolution versus 14.2% on placebo (P<0.001). [2] Fibrosis improvement of at least one stage occurred in 25.9% of the 100-mg group versus 14.2% placebo (P<0.001). [2]

These are meaningful adult outcomes. They say nothing about what resmetirom would do in a 7-year-old with a 22 kg body weight, a still-developing thyroid axis, and hepatic cytochrome P450 enzyme activity that differs from an adult's by a factor of 2 to 4 for certain isoforms.

Safety Profile in Adults

In MAESTRO-NASH, the most common adverse events were gastrointestinal: nausea (26% resmetirom vs. 11% placebo) and diarrhea (22% vs. 13%). [2] Serious adverse events occurred in 11% of the resmetirom group. ALT and AST elevations were observed in a subset of patients, leading to dose interruption or discontinuation in some cases. Cardiac adverse events were not significantly different between groups. These adult safety signals do not automatically translate to children, where baseline hepatic and thyroid physiology differs.

Thyroid Biology in Children: A Key Safety Concern

Resmetirom's mechanism involves selective agonism of the thyroid hormone receptor-beta isoform in hepatocytes. In adults, THR-beta selectivity is designed to produce the lipid-lowering and hepatic metabolic benefits of thyroid hormone without activating the THR-alpha receptor in cardiac tissue or bone. [3]

Developmental Thyroid Physiology Under Age 12

Children under 12 are in active thyroid-dependent developmental phases. Thyroid hormone governs brain myelination through age 3, linear bone growth through puberty, and the regulation of hepatic lipid metabolism throughout childhood. The THR-beta isoform is expressed not only in adult hepatocytes but also in developing cochlear tissue, the retina, and the anterior pituitary in children. [4]

No preclinical or clinical data describe what chronic THR-beta agonism does to these tissues during childhood development. Animal developmental toxicology studies for resmetirom have not been publicly disclosed in pediatric-relevant detail. This is not a theoretical risk to dismiss, it is an unstudied domain.

Hepatic Drug Metabolism in Children Under 12

CYP2C8 is the primary cytochrome P450 isoform responsible for resmetirom metabolism. CYP2C8 activity in children under 5 is approximately 40% of adult activity, rising to near-adult levels by age 10-12. [5] No pediatric pharmacokinetic modeling for resmetirom has been published, meaning the right dose in a 9-year-old is genuinely unknown, not just unapproved. Underdosing risks subtherapeutic exposure; overdosing risks amplified hepatic or thyroid-axis effects.

Pediatric MASLD: Current Standard of Care

No pharmacotherapy is currently approved for MASLD or MASH in any pediatric age group in the United States. The 2023 American Association for the Study of Liver Diseases (AASLD) practice guidance on NAFLD/NASH states that "lifestyle intervention remains the cornerstone of management in pediatric NAFLD." [6]

Lifestyle Intervention Evidence

The TONIC trial (N=173, ages 8-17) evaluated vitamin E and metformin against placebo in pediatric NAFLD. Neither active arm achieved its primary endpoint of sustained ALT reduction. [7] Vitamin E did show histological improvement in a secondary analysis, and some clinicians use it off-label, but it is not FDA-approved for this indication either.

A 2021 systematic review in Hepatology covering 34 pediatric NAFLD trials found that dietary modification producing 7-10% body weight reduction consistently improved ALT levels and hepatic steatosis on imaging, though biopsy-confirmed fibrosis improvement data in children remain sparse. [8]

What Clinicians Should Do Instead

For children under 12 with biopsy-confirmed or imaging-diagnosed MASLD:

• Refer to a pediatric hepatologist for staging and monitoring.
• Initiate structured dietary modification targeting a 7-10% reduction in body weight relative to ideal.
• Evaluate for metabolic comorbidities: type 2 diabetes, dyslipidemia, hypertension.
• Consider vitamin E (400-800 IU/day) only after specialist consultation and with acknowledgment of off-label status and limited evidence.
• Do not initiate resmetirom. No safety data exist, and no dosing guidance is available.

Pharmacokinetics and Growth: What We Know From Related Drug Classes

The closest pharmacological precedent for resmetirom in a younger population comes from thyroid hormone replacement in pediatric hypothyroidism. Levothyroxine (LT4) is routinely used in children, including neonates, with well-characterized weight-based dosing and growth monitoring protocols. [9] However, LT4 replaces deficient endogenous hormone; resmetirom adds exogenous THR-beta stimulation on top of a normal thyroid axis. The physiological implications are different.

Lessons From Sobetirome Research

Sobetirome, an earlier THR-beta selective agonist, was studied in adults for cholesterol lowering in the mid-2000s. Its development was halted partly due to concerns about suppression of the hypothalamic-pituitary-thyroid (HPT) axis at higher doses. [10] Resmetirom's selectivity is more refined, but the HPT axis suppression risk remains a signal that would need formal pediatric study before any clinical use in children.

Bone Density Considerations

Thyroid hormone excess in childhood accelerates bone age and can reduce adult height. The AACE clinical practice guidelines for pediatric thyroid disorders note that even mild supraphysiologic thyroid hormone exposure in children requires monitoring of bone age by wrist radiograph every 6-12 months. [11] Because resmetirom theoretically could suppress endogenous TSH via HPT axis feedback, long-term bone effects in a growing child would need study.

Regulatory Pathway: When Might Pediatric Data Become Available?

Under the Pediatric Research Equity Act (PREA), the FDA can require pediatric studies for drugs used in pediatric populations when the disease exists in children. MASLD clearly occurs in children. The FDA may have issued a PREA deferral to Madrigal Pharmaceuticals, allowing adult approval first with pediatric studies to follow on a negotiated timeline.

What a Pediatric PK Study Would Need to Cover

A minimal pediatric development program for resmetirom would include:

1. An open-label pharmacokinetic study in at least two pediatric age cohorts (2-12 and 12-18 years), likely 16-24 patients per cohort per FDA guidance on pediatric studies. [12]
2. Safety monitoring for TSH suppression, ALT/AST changes, and growth velocity over at least 12 months.
3. Histological endpoints in a subset if feasible, or validated non-invasive biomarkers (MRI-PDFF, ELF score) as surrogate primary endpoints.

No such trial is currently listed on ClinicalTrials.gov for resmetirom in pediatric patients as of the date of this article's last review.

The FDA's Pediatric Drug Safety Initiative

The FDA's Office of Pediatric Therapeutics tracks postmarket pediatric commitments. The FDA's pediatric drug development framework, outlined in its guidance "General Principles for Pediatric Pharmacokinetic Studies," emphasizes that children are not simply small adults, dose linearity, protein binding, and organ maturity all require independent assessment. [13]

Drug Interactions and Comorbidity Considerations in Children

Children under 12 with MASH frequently have concurrent metabolic conditions: obesity, insulin resistance, dyslipidemia, and sometimes type 2 diabetes. Each introduces potential drug-interaction concerns if resmetirom were ever studied or used off-label.

CYP2C8 Inhibitors Common in Pediatric Practice

Resmetirom is a CYP2C8 substrate. Gemfibrozil, a strong CYP2C8 inhibitor, is sometimes used off-label in pediatric dyslipidemia and is listed as a contraindicated co-administration in the adult Rezdiffra label. [1] Trimethoprim, used in pediatric urinary tract infections, is a moderate CYP2C8 inhibitor. In a child already receiving these agents, resmetirom plasma concentrations could increase substantially from an already-undefined baseline.

Statin Co-Administration

The adult Rezdiffra label warns that resmetirom increases statin plasma concentrations through OATP1B1/1B3 transporter inhibition, requiring statin dose adjustment. [1] Rosuvastatin's AUC increased 4.7-fold in the adult drug interaction study. [1] Statins are used increasingly in pediatric familial hypercholesterolemia starting at age 8-10. Co-administration risk in this scenario would be completely uncharacterized.

What Parents Should Know: A Direct Summary

Parents of children with fatty liver disease often find resmetirom in online searches and ask their child's physician about it. Here is what the evidence supports telling them:

Resmetirom works in adults. The MAESTRO-NASH trial showed real, biopsy-confirmed liver improvement in adults with MASH. [2] That is meaningful progress for a disease with no prior approved treatment.

Children are not adults from a drug-safety standpoint. A child's liver metabolizes drugs differently, the thyroid axis is still driving growth and brain development, and the dose that is safe in a 90 kg adult may be toxic in a 30 kg child.

Off-label use carries no safety net. Without a pharmacokinetic study, a clinician giving resmetirom to a 9-year-old has no dosing guidance, no safety stopping rules derived from pediatric data, and no regulatory framework protecting that child.

The right path is specialist referral and lifestyle change. A pediatric hepatologist can stage the disease, monitor progression, and enroll the child in a clinical trial if one opens.

Monitoring Children With MASH Who Are Not on Pharmacotherapy

Children with confirmed MASH and fibrosis require active monitoring even without pharmacotherapy. The AASLD 2023 guidance recommends liver enzyme monitoring every 3-6 months and imaging reassessment annually in children with MASLD who have risk factors for progression. [6]

Laboratory Panels

• ALT, AST, GGT every 3-6 months.
• Fasting glucose, insulin (HOMA-IR calculation), HbA1c annually.
• Fasting lipid panel annually.
• TSH annually (baseline and ongoing, especially if thyroid symptoms arise).

Imaging

Liver ultrasound is the first-line imaging tool. MRI-PDFF (proton density fat fraction) provides more accurate quantification of hepatic steatosis and may be appropriate in centers with pediatric MRI capability. [14] Vibration-controlled transient elastography (FibroScan) is validated in children over 2 years and provides non-invasive fibrosis staging. [15]

When to Consider Liver Biopsy

Biopsy remains the reference standard for MASH diagnosis and fibrosis staging. In children, biopsy is reserved for cases where non-invasive markers suggest F2 or higher fibrosis, where diagnosis is uncertain, or where a clinical trial requires histological confirmation. The risks of sedation and procedural complications in children must be weighed against the diagnostic gain in each case.